Publications

Baseline Platelet Count and Body Weight as Predictors of Early Dose Modification in the Quadra Trial of Niraparib Monotherapy for the Treatment of Heavily Pretreated (≥4Th Line), Advanced, Recurrent High-Grade Serous Ovarian Cancer

AuthID
P-00V-T9P

Author(s)

Matulonis, U

Monk, B

Secord, A

Geller, M

Miller, D

Cloven, N

Fleming, G

Hendrickson, AW

Azodi, M

DiSilvestro, P

Oza, A

Cristea, M

Berek, J

Chan, J

Li, Y

Luptakova, K

Hazard, S

Moore, K

Document Type

Article

Year published

2019

Published

in Gynecologic Oncology, ISSN: 0090-8258

Volume: 154, Pages: 3

Indexing

Crossref^®6

Google Scholar^®

Publication Identifiers

DOI: 10.1016/j.ygyno.2019.04.017

Source Identifiers

ISSN: 0090-8258

Export Publication Metadata

Marked List

Add to Marked List

Citations

Oops! It looks like you don't have access to this content.

This section is restricted to uses with b-on access.

CORE Conference

No information about CORE Rank

During the preprocessing phase, only publications of type 'Proceedings Paper' or 'Proceedings' are automatically processed to identify their CORE Rank.

TIP: If your publication's CORE Rank is missing, you can contact with your institutional manager to have the correct ranking manually added to the record.

Journal Factors

Oops! It looks like you don't have access to this content.

This section is restricted to uses with b-on access.

Full Text

Full Text @ sfx.b-on.pt

Baseline Platelet Count and Body Weight as Predictors of Early Dose Modification in the Quadra Trial of Niraparib Monotherapy for the Treatment of Heavily Pretreated (≥4Th Line), Advanced, Recurrent High-Grade Serous Ovarian Cancer

Useful Links

Get Help

Federated Authentication (Click on the image)

Baseline Platelet Count and Body Weight as Predictors of Early Dose Modification in the Quadra Trial of Niraparib Monotherapy for the Treatment of Heavily Pretreated (≥4Th Line), Advanced, Recurrent High-Grade Serous Ovarian Cancer

Useful Links

Get Help